Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Tardive Dyskinesia Excellence Forum

Tardive Dyskinesia
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Craig Chepke, MD, FAPA
Your Questions Answered
Is high blink rate a symptom of Tardive Dyskinesia? With Dr Craig Chepke
12/07/2022
Dr Chepke answers questions surrounding TD: high blink rate and AIMS exam over telehealth.
Dr Chepke answers questions surrounding TD: high blink rate and AIMS exam over telehealth.
Dr Chepke answers questions...
12/07/2022
Psych Congress Network
Pop quiz.
Expert Insights Quiz
Which Areas of Patients' Lives Does Tardive Dyskinesia Negatively Impact?
11/22/2022
Test your clinical knowledge with this quick quiz!
Test your clinical knowledge with this quick quiz!
Test your clinical knowledge...
11/22/2022
Psych Congress Network
Desiree Matthews, PMHNP-BC.
Videos
Provider Misconceptions About Tardive Dyskinesia
11/15/2022
In this video, Desiree Matthews, PHMNP-BC, addresses common misconceptions about tardive dyskinesia among health care providers and details how VMAT2 inhibitors can help improve the symptoms of TD.
In this video, Desiree Matthews, PHMNP-BC, addresses common misconceptions about tardive dyskinesia among health care providers and details how VMAT2 inhibitors can help improve the symptoms of TD.
In this video, Desiree Matthews,...
11/15/2022
Psych Congress Network
Quiz
What percentage of patients taking deutetrabenazine for TD saw adverse events?
10/16/2022
Time for a pop quiz! Test your tardive dyskinesia knowledge.
Time for a pop quiz! Test your tardive dyskinesia knowledge.
Time for a pop quiz! Test your...
10/16/2022
Psych Congress Network
Rakesh Jain
Quiz
Can the Semiformal Movement Disorder Assessment Replace AIMS?
07/08/2022
True or false? Clinicians can replace the AIMS assessment with the semiformal movement disorder assessment process performed more regularly at appointments with patients taking antipsychotic medication.
True or false? Clinicians can replace the AIMS assessment with the semiformal movement disorder assessment process performed more regularly at appointments with patients taking antipsychotic medication.
True or false? Clinicians can...
07/08/2022
Psych Congress Network
TD MOA
Anticholinergics and VMAT-2 Inhibitors: Different MOAs, Different Results
05/09/2022
This video shows the importance of understanding the mechanism of action that is associated with better treating tardive dyskinesia.
This video shows the importance of understanding the mechanism of action that is associated with better treating tardive dyskinesia.
This video shows the importance...
05/09/2022
Psychiatry & Behavioral Health
News
First Exposure to Deutetrabenazine Well-Tolerated Across Patient Populations
01/11/2022
Analysis of safety data for deutetrabenazine suggests the drug is generally safe and well-tolerated in both tardive dyskinesia and chorea associated with Huntington's disease patient populations.
Analysis of safety data for deutetrabenazine suggests the drug is generally safe and well-tolerated in both tardive dyskinesia and chorea associated with Huntington's disease patient populations.
Analysis of safety data for...
01/11/2022
Psych Congress Network
goldberg
Podcasts
The Link Between Lithium Use and Tardive Dyskinesia
12/29/2021
Dr Joseph Goldberg provides information on how lithium use for bipolar disorder can cause tardive dyskinesia and how to correctly identify and address this problem.
Dr Joseph Goldberg provides information on how lithium use for bipolar disorder can cause tardive dyskinesia and how to correctly identify and address this problem.
Dr Joseph Goldberg provides...
12/29/2021
Psych Congress Network
Dr Jain, Kumar, Meyer
Podcasts
Tardive Dyskinesia: Medication Management, Your Questions Answered
12/06/2021
In Part 2 of this podcast, Rakesh Jain, MD, MPH, Psych Congress steering committee member, continues the Q&A session with Rajeev Kumar, MD, and Jonathan M. Meyer, MD, on their Psych Congress session titled "Tardive Dyskinesia Across the...
In Part 2 of this podcast, Rakesh Jain, MD, MPH, Psych Congress steering committee member, continues the Q&A session with Rajeev Kumar, MD, and Jonathan M. Meyer, MD, on their Psych Congress session titled "Tardive Dyskinesia Across the...
In Part 2 of this podcast,...
12/06/2021
Psych Congress Network
Jain
Podcasts
Tardive Dyskinesia, Comorbidities and Treatment Options
12/02/2021
Rakesh Jain, MD, MPH, guides a Q&A session with Rajeev Kumar, MD, and Jonathan M Meyer, MD, on their Psych Congress session titled "Tardive Dyskinesia Across the Complexity Spectrum – From Quality of Life Improvement to Novel Treatments."
Rakesh Jain, MD, MPH, guides a Q&A session with Rajeev Kumar, MD, and Jonathan M Meyer, MD, on their Psych Congress session titled "Tardive Dyskinesia Across the Complexity Spectrum – From Quality of Life Improvement to Novel Treatments."
Rakesh Jain, MD, MPH, guides a...
12/02/2021
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement